3 November 2021
At the meeting of 6 October 2021 the RMA:
Determined Statements of Principles (SOPs) for:
| Condition | SOPs | |
|---|---|---|
| chronic fatigue syndrome | 105/2021 | 106/2021 |
| fibromyalgia | 107/2021 | 108/2021 |
These SOPs revoke the SOPs previously determined for these conditions.
The above SOPs take effect from 22 November 2021.
Summary of Changes
Decided to Undertake Consultation regarding:
| Condition | Reasons for Decision | Date for Final Decision |
|---|---|---|
| heart block | Intention to remove one or more factors | February 2022 |
| periodontitis | Intention to remove one or more factors | February 2022 |
| periodontal abscess | Intention to remove one or more factors | February 2022 |
Completed Investigations
The above determinations conclude the previously advertised investigations into:
New Investigations
Decided to advertise the following investigations:
- Hodgkin lymphoma
- cervical spondylosis
- hiatus hernia
- warts
- peripheral neuropathy
- Creutzfeldt-Jakob disease
- vascular neurocognitive disorder
- malignant neoplasm of unknown primary site
- posttraumatic stress disorder
- mature B-cell lymphoid leukaemia and small lymphocytic lymphoma (chronic lymphocytic leukaemia/small lymphocytic lymphoma)
- intervertebral disc prolapse
- thoracic spondylosis
- lumbar spondylosis
- chronic obstructive pulmonary disease
- malignant neoplasm of the thyroid gland
- acute stress disorder
- mitral valve prolapse
- pleural plaque
- atrial fibrillation and atrial flutter
- otitis media
- malignant neoplasm of the prostate
- malignant neoplasm of the stomach
- melioidosis
- suicide and attempted suicide (focussed review - gender dysphoria)
The above investigation notices appear in the Government Notices Gazette of 2 November 2021.